mal was Positives: soeben Ausbruch bei Collagenex(CGPI) - 500 Beiträge pro Seite

[curiosus]

Kennt vielleicht ja niemand hier.
Aber ich möchte mal darauf aufmerksam machen.

[Chalifmann3]

CollaGenex Pharmaceuticals Reports Record Revenues and Earnings in the Second Quarter of 2003

Tuesday July 22, 7:30 am ET
Net Income Allocable to Common Stockholders was $0.10 per Share on Revenues of $12.7 Million

NEWTOWN, Pa.--(BUSINESS WIRE)--July 22, 2003-- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI - News) today reported financial results for the second quarter ended June 30, 2003. Total revenues increased 16% to $12.7 million compared to $11.0 million in the second quarter of 2002. Net product sales were $11.8 million in the second quarter of 2003, a 13% increase over net product sales of $10.4 million recorded in the second quarter of 2002.

ADVERTISEMENT
During the second quarter of 2003, net income was $1.6 million compared to a net loss of $385,000 during the second quarter of 2002. Net income allocable to common stockholders for the second quarter of 2003 was $1.2 million, or $0.10 per basic and diluted share, compared to a net loss of $794,000, or $0.07 per basic and diluted share, in the second quarter of 2002.

"We are pleased to have reported our fourth consecutive quarter of increased profitability. Our continued ability to deliver solid operating results is a testament to the ongoing market penetration by our sales force and acceptance of our dental and dermatology products," stated Brian M. Gallagher, PhD, chairman, president and chief executive officer of CollaGenex. "The introduction of the AVAR product line has significantly enhanced the standing of our representatives in the dermatologist`s office and we anticipate solid growth in our dermatology sales as we move into the second half of the year."

"We continue to pursue dermatological indications for Periostat in the clinic, and I am pleased to note that a Phase 3 study evaluating Periostat in the treatment of rosacea is close to full enrollment," Dr. Gallagher continued. "We expect this trial to be completed by the end of 2003. The publication of new data on the use of Periostat in the treatment of acne and rosacea has greatly increased awareness among dermatologists of our development efforts in this field. In addition, we have identified an optimized formulation for a once-a-day version of Periostat, and we are rapidly moving ahead to carry out definitive clinical studies with this formulation ahead of schedule in the second half of 2003. We look forward to continued execution on our stated goals of investing in the future of CollaGenex while increasing our revenues and profitability."

"During the second quarter of 2003, we increased our net product sales by 13%, or $1.4 million, compared to a year ago while reducing our SG&A expense by 14%, or about $1.3 million, over the same period in the prior year," added Nancy C. Broadbent, chief financial officer of CollaGenex. "We continued to invest in our pipeline during the quarter, increasing our R&D spending by about $883,000 over the same period in the prior year, which reflects expenses related to our ongoing clinical trials of Periostat in dermatology and other indications, our once-a-day, sustained release formulation of Periostat and the development of products based on our Restoraderm platform technology."

During the second quarter of 2003, CollaGenex announced a number of additional important achievements related to marketed products and those in clinical development.

* Periostat received final approval for marketing in two additional countries. Periostat will be marketed in Switzerland by Karr Dental AG and in Canada by Pharmascience Inc.
* Positive outcomes of a Phase 2 clinical trial of Periostat in the treatment of moderate facial acne were reported in the April 2003 Archives of Dermatology.
* In rosacea, data from a Phase II study evaluating Periostat in combination with MetroLotion demonstrated that Periostat offers significant benefits for rosacea.
* An independent experience trial that demonstrated favorable results from the use of Periostat as a monotherapy in the treatment of rosacea was published in the July/August issue of the peer-reviewed journal Skin Med.

[Chalifmann3]

Collagenex mentioned in a Wall Street article:

Wall Street Transcript
Biotech Stocks heating up again
Wednesday August 27, 12:48 pm ET

.....
....

For the investor who is more conservative, we recommend CollaGenex Pharmaceuticals. They`re an earnings story in that they actually make money. They market a drug called Periostat. They have a 115-person sales force to market the product, and they leverage this sales force to market other products that they co-promote or end-license from other companies.

TWST: What`s the product for?

Dr. Benjamin: Periostat is prescribed for patients with adult periodontitis. It`s used as an adjunct for scaling and root planing, the primary procedure used to treat individuals with periodontitis. In 2002, total product revenues reached over $40 million. The dental indication is the growth story that Wall Street and investors are aware of.

There`s a hidden growth story that most investors don`t know about, and that is that Periostat has successfully demonstrated positive clinical results in several Phase II studies for dermatology indications such as acne and rosacea. The company has demonstrated positive statistically significant clinical results, in double-blind and placebo-controlled trials, in reducing the symptoms associated with rosacea and acne. CollaGenex is evaluating Periostat in a Phase III trial for rosacea with results expected within five months. If it`s anything like the Phase II trial results, Periostat will open a huge market for CollaGenex - a $1.2 billion market.

Chalifmann

[Chalifmann3]

CollaGenex Pharmaceuticals Reports Record Financial Results in the Third Quarter of 2003

Tuesday October 28, 7:32 am ET

Net Income Allocable to Common Stockholders was $0.13 Per Basic Share and $0.12 per Diluted Share on Revenues of $13.9 Million


NEWTOWN, Pa.--(BUSINESS WIRE)--Oct. 28, 2003-- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI - News) today reported financial results for the third quarter ended September 30, 2003. Total revenues increased 24% to $13.9 million compared to $11.2 million in the third quarter of 2002. Net product sales were $12.8 million in the third quarter of 2003, a 19% increase over net product sales of $10.8 million recorded in the third quarter of 2002.
Net income allocable to common stockholders for the third quarter of 2003 was $1.5 million, or $0.13 per basic share and $0.12 per diluted share, compared to net income allocable to common stockholders of $356,000, or $0.03 per basic and diluted share, in the third quarter of 2002.

"We are pleased with the results of the third quarter of 2003," said Brian M. Gallagher, PhD, chairman, president and chief executive officer of CollaGenex. "We continued to deliver solid operating and financial results, reflecting the diligence of our sales force in expanding market penetration of our dental and dermatology products and the increasing acceptance of these products by physicians."

"In addition to focusing on increasing product sales, we continue to invest in the future of our Company," Dr. Gallagher continued. "We are building our presence in the dermatology market by pursuing dermatological indications for Periostat® in the clinic and by exploring licensing and development opportunities that would enable us further to leverage our sales force. The $18.8 million we recently raised through our shelf offering will facilitate our ability to license and/or develop these dermatology products."

"We also are committed to the defense of Periostat® patents and the development of a sustained release, once-daily formulation of Periostat®. We now have a suitable formulation and plan to enter Phase III clinical trials with this new once-a-day formulation in the second quarter of 2004," concluded Gallagher.

"During the third quarter of 2003, we increased our total revenues by 24%, or $2.7 million, compared to the third quarter of 2002 while increasing our operating expenses by only 15%, or $1.5 million," added Nancy C. Broadbent, chief financial officer of CollaGenex. "Our SG&A expenses were approximately $918,000 higher during the third quarter of 2003 compared to the third quarter of 2002, primarily due to legal expenses we incurred in connection with our patent and FDA litigation that exceeded the amount that could be reimbursed to us by the licensor out of current royalties. We anticipate that we will be reimbursed for patent-related legal costs out of future royalties otherwise payable on future sales of Periostat®. However, legal costs relating to the litigation with the FDA and anti-trust matters are not eligible for reimbursement by the licensor out of royalties."

"We continued to invest in our pipeline during the third quarter of 2003, increasing our R&D spending by about $422,000 over the same period in the prior year. This reflects expenses related to our ongoing clinical trials of Periostat® in dermatology and other indications, our once-a-day, sustained release formulation of Periostat® and the development of products based on our Restoraderm(TM) platform technology," said Ms. Broadbent.

During the first nine months of 2003, CollaGenex recorded $38.8 million in total revenues compared to $33.0 million in total revenues during the first nine months of 2002. Net product sales during the first nine months of 2003 were $35.9 million compared to $31.0 million during the comparable period in 2002. The Company earned net income allocable to common stockholders of $0.31 per basic share and $0.29 per diluted share during the first nine months of 2003 compared to a net loss allocable to common stockholders of $0.13 per basic and diluted share during the first nine months of 2002.

CollaGenex announced a number of additional important achievements during the third quarter of 2003:

-CollaGenex recently completed a $20 million shelf offering in which the Company sold 2.0 million shares of its registered common stock to certain institutional investors at $10 per share. Net proceeds to the Company were approximately $18.8 million after the payment of placement agent fees and related expenses and will be used for general working capital purposes, including possible dermatology product licensing and development opportunities consistent with the Company`s strategy of expanding its presence in the dermatology market.
-Paul Lubetkin was appointed to the newly-created position of senior vice president and general counsel. He oversees all legal affairs at CollaGenex and is a key addition to the CollaGenex management team, particularly given the complexity of the legal issues involving the intellectual property covering Periostat®.
-The United States District Court of the District of Columbia granted a preliminary injunction temporarily restraining the United States Food and Drug Administration from approving any abbreviated new drug applications (ANDAs) submitted for a capsule or tablet generic dosage form of Periostat® (doxycycline hyclate) 20mg.
-CollaGenex completed initial Phase 1 clinical studies of a sustained release, once-daily version of Periostat, thereby establishing the pharmacokinetics of its lead formulation and confirming that the formulation falls within the Company`s pre-defined criteria for maximum serum concentration and total dose delivered.
-CollaGenex initiated a double-blinded, placebo-controlled Phase 2 clinical study to evaluate the safety and efficacy of Col-3, a novel, non-antimicrobial tetracycline derivative, for the treatment of rosacea.
-An independent experience trial that demonstrated favorable results from the use of Periostat® as a monotherapy in the treatment of rosacea was published in the July/August issue of the peer-reviewed journal Skin Med

Chalifmann